Diplomat Releases 2015 Satisfaction Survey Results
FLINT, Mich. – Jan. 21, 2016 – The nation’s largest independent specialty pharmacy reveals 99% patient satisfaction with Diplomat through a third-party survey.
Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today the results from its 2015 patient survey. Every year, Diplomat engages an independent third-party agency to evaluate the levels of satisfaction, study the customer’s experience and track its service delivery performance over time.
For 2015, Diplomat received over 98 percent satisfactions rate from patients in all four-survey categories:
- Overall satisfaction (99 percent)
- Telephone courtesy (99 percent)
- Helpfulness of pharmacists (98 percent)
- Helpfulness of patient care staff (99 percent)
The survey found that 95 percent of patients would recommend Diplomat to their family, friends and co-workers.
“These survey results are a result of all the efforts we’ve undertaken to do whatever it takes to serve our patients,” said Gary Kadlec, Diplomat president. “We continually look to optimize care while maintaining our principal focus on the patient.”
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
@DiplomatRxWe have several open career opportunities. Apply today to join the Diplomat team: https://t.co/Nljmwp5uEI1 day ago
@TruverisRT @Truveris: 1 week until #wcIntegrate kicks off! Join our panel on #copayaccumulators with our VP of Life Sciences, Elizabeth Pattyn, and…3 days ago
@DiplomatRxHeath Nivens, EnvoyHealth's new vice president of client strategy, wrote an interesting piece on modernizing patien… https://t.co/Wdkiz7jad82 weeks ago
@DiplomatRxDon’t forget: Our team is at the @340BCoalition Summer Conference. Visit us in Booth 82 to learn more about our 340… https://t.co/MinIeAYlju2 weeks ago
@DiplomatRxOur team is at the @340BCoalition Summer Conference. Stop by Booth 82 to learn how we can expand your 340B savings… https://t.co/8BC2pqFavH2 weeks ago